Live Analysis
Novavax, Inc. (NVAX) currently trades at $7.88, marking a decrease of -18.49 cents (-2.29%) from the previous close of $8.06. The trading volume stands at $1.26 million, 30.58% above the average. Despite the price dip, NVAX displays consistent trading activity.
Earnings Overview
The latest quarterly earnings report for NVAX was released on Wednesday, February 25th, with a consensus EPS estimate of -0.66. While revenue and earnings data are not provided, the company's earnings performance is in focus.
Cash Flow
NVAX reports a net change in cash of -$27.30 million, with an operating cash flow of -$39.48 million. Notable outflows include $41.55 million in free cash flow and $6.27 million in debt repayment, reflecting ongoing financial activities.
Income Statement
The company generated $147.14 million in revenue, resulting in a net income of $17.53 million. Operating income stands at $21 million, with an EPS and EPS diluted of 11 cents each, based on a weighted average of shares outstanding.
Ratios
Key ratios for NVAX include a gross profit margin of 82.87% and a return on assets of 1.49. Notably, the debt equity ratio is -194.76, and the price to earnings ratio is 15.53, indicating the company's financial position.
Balance Sheet
NVAX's balance sheet highlights total assets of $1.18 billion, with $978.28 million in total current assets. Total liabilities amount to $1.30 billion, with a net debt of $8.18 million.
This comprehensive analysis showcases NVAX's financial standing amidst market fluctuations, revealing both strengths and areas for potential growth.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.